[Study on the rationale for chemotherapy of refractory choriocarcinoma].
The combination chemotherapy consisting of methotrexate (MTX), actinomycin D (ACD), and an alkylating agent was applied to the high risk patients refractory to MTX and/or ACD. The remission rate of the high risk group was about 70% and that of low risk patients was 100%. It is important to seek an effective chemotherapy for patients refractory to the above combined chemotherapy; therefore, we tried out the following regimens: (1) Quadritherapy with MTX, ACD, CPM and vincristine; (2) CHAMOMA protocol; (3) cis-platinum, bleomycin and vinblastine therapy; (4) ultra high dose MTX therapy and (5) the combination chemotherapy without MTX. The last regimen was designed based on the experimental data chemotherapy using nude mice.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001761:Bleomycin / Q000008:administration & dosage; D002822:Choriocarcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D011247:Pregnancy; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001761:Bleomycin; D003609:Dactinomycin; D014750:Vincristine; D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate